Correction: 3D quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies (PLoS ONE (2012) 8, 3 (e59691) DOI: 10.1371/journal.pone.0059691);D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Righi, Marco ^a,b   Giacomini, Arianna ^c   Cleris, Loredana ^d   Carlo Stella, Carmelo ^b,c  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; ARTIFACT REDUCTION; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE PROCESSING; LYMPHOMA; MICROVESSEL CROSS SECTIONAL AREA; MICROVESSEL DIAMETER; MICROVESSEL DISTRIBUTION; MICROVESSEL QUANTITY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; STAINING; THREE DIMENSIONAL IMAGING; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR TARGETED THERAPY; VESSEL SKELETONIZATION; ANIMAL; ARTIFACT; CELL TRANSFORMATION; DRUG EFFECT; METABOLISM; METHODOLOGY; MICROVASCULATURE; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTIFACTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LYMPHOMA; MICE; MICE, INBRED NOD; MICE, SCID; MICROVESSELS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 84875425570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/annotation/f61040ca-4eab-4c4c-ad77-0a2ab8c503de     Document Type: Erratum

References (46)

1. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
2. Folkman J, (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
3. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, et al. (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11: 416-420.
4. Carmeliet P, Jain RK, (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
5. McKeage MJ, Baguley BC, (2010) Disrupting established tumor blood vessels. Cancer 116: 1859-1871.
6. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, et al. (1996) Time dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770.
7. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
8. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736.
9. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, et al. (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13: 3942-3950.
10. Zhang C, Wu R, Zhu H, Hu Y, Jiang H, et al. (2011) Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo. Cancer Lett 302: 11-19.
11. Reyes-Aldasoro CC, Williams LJ, Akerman S, Kanthou C, Tozer GM, (2011) An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections. J Microsc 242: 262-278.
12. Zudaire E, Gambardella L, Kurcz C, Vermeren S, (2011) A computational tool for quantitative analysis of vascular networks. PLoS One 6: e27385.
13. Seaman ME, Peirce SM, Kelly K, (2011) Rapid analysis of vessel elements (RAVE): a tool for studying physiologic, pathologic and tumor angiogenesis. PLoS One 6: e20807.
14. Kocińsky M, Klepaczko A, Materka A, Chekenya M, Lundervold A, (2011) 3D image texture analysis of simulated and real-world vascular trees. Comput Methods Programs Biomed 107: 140-154.
15. Weidner N, Sample JP, Welch WR, Folkman J, (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
16. Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A, et al. (2008) Evaluation of microvascular density in tumous: pro and contra. Histol Histopathol 23: 601-607.
17. Righi M, Giacomini A, Lavazza C, Sia D, Carlo-Stella C, et al. (2009) A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. Lab Invest 89: 1063-1070.
18. Folkman J, Kalluri R (2003) Tumor Angiogenesis. In: Kufe DW, PollockRE, WeichselbaumRR, BastJrRC, HollandJF, FreiEIII(eds) Cancer Medicine, 6th edn, BC Decker Inc, Hamilton, Ontario, 161-194.
19. Namba M, Ohtsuki T, Mori M, Togawa A, Wada H, et al. (1989) Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol 25: 723-729.
20. Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, et al. (2010) Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 115: 2231-2240.
21. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibit tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851--11858.
22. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, et al. (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053--1062.
23. Hill SA, Chaplin DJ, Lewis G, Tozer GM, (2002) Schedule dependence of combretastatin A4 phospate in transplanted and spontaneous tumour models. Int. J. Cancer 102: 70-74.
24. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, et al. (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2: 291-298.
25. Cunningham IA, Fenster A, (1987) A method for modulation transfer function determination from edge profiles with correction for finite-element differentiation. Med Phys 14: 533-537.
26. Meijering EHW, Niessen WJ, Viergever MA, (2001) Quantitative evaluation of convolution-based methods for medical image interpolation. Med Image Anal 5: 111-126.
27. Lee T-C, Kashyap RL, Chu C-N, (1994) Building skeleton models via 3-D medial surface/axis thinning algorithms. Comput Vis Graph Image Process 56: 462-478.
28. Serra J (1983) Image analysis and mathematical morphology. Academic Press, New York.
29. R Development Core Team (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna.
30. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
31. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, et al. (2003) Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46: 1116-1119.
32. Chow LQ, Eckhardt SG, (2007) Sunitinib: from rationale design to clinical efficacy. J Clin Oncol 25: 884-896.
33. Dark GD, Hill SA, Prise VE, Tozer GM, Pettit GR, et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834.
34. Prise VE, Honess DJ, Stratford MRL, Wilson J, Tozer GM, (2002) The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21: 717-726.
35. Soltanian-Zadeh H, Shahrokni A, Khalighi MM, Zhang Z, Zoroofi R, et al. (2005) 3-D quantification and visualization of vascular structures from confocal microscopic images using skeletonization and voxel-coding. Comput Biol Med 35: 791-813.
36. Tozer G M, Prise VE, Wilson J, Cezamar M, Shan S, et al. (2001) Mechanisms associated with tumor vascular shut-down induced by combretastain A-4 phospate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413-6422.
37. Plouraboué F, Cloetens P, Fonta C, Steyer A, Lauwers F, et al. (2004) X-ray high-resolution vascular network imaging. J Microscopy 215: 139-148.
38. Müller B, Fischer J, Dietz U, Thurner PJ, Beckmann F, (2006) Blood vessel staining in the myocardium for 3D visualization down to the smallest capillaries. Nucl Instrum Meth Phys Res B 246: 254-261.
39. Lang S, Müller B, Dominietto MD, Cattin PC, Zanette I, et al. (2012) Three-dimensional quantification of capillary networks in healthy and cancerous tissues of two mice. Microvasc Res 84: 314-322.
40. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337.
41. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM, (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478.
42. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, et al. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605.
43. Adnane L, Trail PA, Taylor I, Wilhelm SM, (2005) Sorafenib (BAY 43-9006, Nexavar(R)), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612.
44. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, et al. (2006) Pericytes limit tumor cell metastasis. J Clin Invest 116: 642-651.
45. Pàez-Ribes M, Allen E, Hudock J, Takeda T, OkuyamaH, et al, (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
46. Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.